Results 131 to 140 of about 260,030 (390)

Analysis of the benefit of anti-PD-1 monotherapy according to NGS-diagnosed genetic alterations in patients with non-small cell lung cancer

Exploration of Targeted Anti-tumor Therapy
Aim: Immune checkpoint inhibitors improved the survival of advanced non-small cell lung cancer. However, only 20% of patients respond to these treatments and the search for predictive biomarkers of response is still topical. The objective of this work is
Hortense De Saint Basile, Reza Elaidi, Zineb Maaradji, Hélène Blons, Rym BenDhiab, Laure Gibault, Elizabeth Fabre   +6 more
doaj   +1 more source

Izbira lokacije za postavitev geomagnetnega observatorija v Sloveniji : Site selection for a permanent geomagnetic observation station in Slovenia [PDF]

Geodetski Vestnik, 2010
Raziskave na področju geomagnetizma lahko označimo kot prve raziskave na področju geofizike. Opazovanje geomagnetnega polja je bistvenegapomena za razumevanje temeljnih postopkov v središču Zemlje, njeni skorji in bližnji okolici planeta Zemlja.
Dejan Paliska, Rudi Čop, Daša Fabjan, Samo Drobne   +3 more
doaj  

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors

OncoImmunology, 2021
T-cell receptor (TCR) redirected T cells are considered as the next generation of care for the treatment of numerous solid tumors. KRAS mutations are driver neoantigens that are expressed in over 25% of all cancers and are thus regarded as ideal targets ...
Pierre Dillard, Nicholas Casey, Sylvie Pollmann, Patrik Vernhoff, Gustav Gaudernack, Gunnar Kvalheim, Sébastien Wälchli, Else Marit Inderberg   +7 more
doaj   +1 more source

Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors [PDF]

, 2019
Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), and both are widely used in combination with chemotherapy or as monotherapy to treat patients with RAS wild-type metastatic ...
Aderka, Dan, García Foncillas, Jesús, Ronga, Philippe, Stintzing, Sebastian, Sunakawa, Yu, Wainberg, Zev, Witzler, Pauline   +6 more
core   +1 more source

Rational Design of Metal–Organic Frameworks for Pancreatic Cancer Therapy: from Machine Learning Screening to In Vivo Efficacy

Advanced Materials, EarlyView.
This work explores the MOF landscape to select a single, optimal candidate for successfully delivering cancer drugs (gemcitabine, paclitaxel, SN‐38) into tough pancreatic tumors. Machine learning and simulations guide this search, demonstrating colloidal stability, excellent biocompatibility, cellular uptake, and sustained release.
Francesca Melle, Dhruv Menon, João Conniot, Jon Ostolaza‐Paraiso, Sergio Mercado, Jhenifer Oliveira, Xu Chen, Bárbara B. Mendes, João Conde, David Fairen‐Jimenez   +9 more
wiley   +1 more source

KRA inefficient ?

, 2020
Coverage ...
openaire   +1 more source

eIF4A inhibitors suppress cell-cycle feedback response and acquired resistance to CDK4/6 inhibition in cancer [PDF]

, 2019
CDK4/6 inhibitors are FDA-approved drugs for estrogen receptor-positive (ER+) breast cancer and are being evaluated to treat other tumor types, including KRAS-mutant non-small cell lung cancer (NSCLC).
Cencic, Regina, Foulkes, William D., Fu, Zheng, Guiot, Marie-Christine, Huang, Sidong, Kong, Tim, Monast, Anie, Park, Morag, Pelletier, Jerry, Pilon, Virginie, Porco, John A., Sangwan, Veena, Xue, Yibo, Zhu, Xianbing   +13 more
core   +1 more source

MUTE‐Seq: An Ultrasensitive Method for Detecting Low‐Frequency Mutations in cfDNA With Engineered Advanced‐Fidelity FnCas9

Advanced Materials, EarlyView.
An advanced‐fidelity CRISPR nuclease, FnCas9‐AF2, is rationally engineered to discriminate single‐base mismatches with unprecedented level precision. Integrated into the MUTE‐Seq workflow, FnCas9‐AF2 depletes wild‐type cell‐free DNA, thereby exposing rare tumor‐derived mutant DNA (a molecular “needle in a haystack”).
Sunghyeok Ye, Jin‐Soo Kim, Myungshin Kim, Ki‐Yeon Kim, Yoon‐Ho Won, Taegun Park, Sungjae An, Haerin Jeong, Hee‐Joon Chung, In Seon Lee, Myoung‐Hee Kang, Chan Young Kang, Mi Young Kim, Jae Ho Chung, Jeong‐An Gim, Woochang Hwang, Yonggoo Kim, Song Cheol Kim, Sungho Lee, Junho K Hur, Junseok W Hur   +20 more
wiley   +1 more source

Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. [PDF]

, 2017
Recent genomic analyses have revealed substantial tumor heterogeneity across various cancers. However, it remains unclear whether and how genomic heterogeneity is constrained during tumor evolution.
Bivona, Trever G, Cai, Mei-Chun, Chen, Hong-Zhuan, Chen, Minjiang, Fu, Yujie, Gao, Wei-Qiang, Gu, Zhenyu, Jing, Ying, Ma, Pengfei, Shen, Ying, Wang, Mengzhao, Wu, Jie, Yan, Ying, Zhang, Shengzhe, Zhao, Xiaojing, Zhu, Liang, Zhuang, Guanglei   +16 more
core   +2 more sources

Advances and Strategies in Enhancing mRNA Cancer Vaccines

Advanced Materials, EarlyView.
Messenger RNA (mRNA) vaccines offer a powerful approach for cancer immunotherapy, but their clinical impact remains limited by delivery challenges and suboptimal immune activation. This review discusses key biological barriers and design strategies—including structural optimization, immunomodulation, organ targeting delivery, and advanced nanocarriers ...
Miao Zhang, Shengqi Chen, Haijun Hu, Yenhui Ong, Qianqian Ni   +4 more
wiley   +1 more source